Large pharmaceutical companies are eager to talk about their digital transformation and their whole-hearted adoption of computational biology and artificial intelligence (AI). In the same vein, many are enthusiastically emphasizing the contributions digital pathology is making throughout their R&D organizations.
Digital pathology is helping pharma across the spectrum of drug discovery and development. (See Exhibit 1.) The technology digitizes hematoxylin...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?